TY - JOUR
T1 - Association of insulin resistance with breast, ovarian, endometrial and cervical cancers in non-diabetic women
AU - Sun, Wanwan
AU - Lu, Jieli
AU - Wu, Shengli
AU - Bi, Yufang
AU - Mu, Yiming
AU - Zhao, Jiajun
AU - Liu, Chao
AU - Chen, Lulu
AU - Shi, Lixin
AU - Li, Qiang
AU - Yang, Tao
AU - Yan, Li
AU - Wan, Qin
AU - Liu, Yan
AU - Wang, Guixia
AU - Luo, Zuojie
AU - Tang, Xulei
AU - Chen, Gang
AU - Huo, Yanan
AU - Gao, Zhengnan
AU - Su, Qing
AU - Ye, Zhen
AU - Wang, Youmin
AU - Qin, Guijun
AU - Deng, Huacong
AU - Yu, Xuefeng
AU - Shen, Feixia
AU - Chen, Li
AU - Zhao, Liebin
AU - Wang, Tiange
AU - Sun, Jichao
AU - Xu, Min
AU - Xu, Yu
AU - Chen, Yuhong
AU - Dai, Meng
AU - Zhang, Jie
AU - Zhang, Di
AU - Lai, Shenghan
AU - Li, Donghui
AU - Ning, Guang
AU - Wang, Weiqing
N1 - Funding Information:
The authors are highly appreciative of all the field workers and participants who contributed to this research and the REACTION Study Group. This work is supported by the grants 2013BAI09B13 from the National Clinical Research Center for Metabolic Diseases, 201502007 from the Ministry of Health, 2015BAI12B14 and 2016YFC0901200 from the Ministry of Science and Technology, 2015CB553601 from the National Basic Research Program of China (973 Program), and 81321001, 81390350, 81130016, 8156-1128019 from the National Natural Science Foundation of China.
PY - 2016
Y1 - 2016
N2 - Hyperinsulinemia and insulin resistance were reported to play a crucial role in diabetes-cancer relationship. This study aimed to explore the associations between insulin resistance and several female cancers in a non-diabetic population. This cross-sectional study was conducted in 121,230 middle-aged and elderly non-diabetic women. Cancer diagnosis was self-reported and further validated by medical records. Insulin resistance was defined as homeostasis model assessment of insulin resistance (HOMA-IR) ≥ 2.50. The prevalence of both premenopausal and postmenopausal breast cancer, postmenopausal ovarian cancer and premenopausal endometrial cancer were higher in insulin-resistant participants than in insulin-sensitive participants (premenopausal breast cancer, 0.45 vs 0.28%; postmenopausal breast cancer, 0.86 vs 0.63%; postmenopausal ovarian cancer, 0.17 vs 0.09%; premenopausal endometrial cancer, 0.43 vs 0.25%, respectively, all P < 0.05). Individuals with insulin resistance had higher odds ratio (OR) of breast cancer, both premenopausal and postmenopausal (OR 1.98, 95% confidence interval (CI) 1.19-3.32; OR 1.29, 95% CI 1.01-1.63), postmenopausal ovarian cancer (OR 2.17, 95% CI 1.10-3.40) as well as total endometrial cancer (OR 1.47, 95% CI 1.02-2.12). Subgroup analysis revealed that the possitive association between insulin resistance and risk of prevalent breast cancer was observed in popualtion with younger age, overweight or obesity, higher education and impaired glucose tolerance (IGR). No relationships were observed for the risk of prevalent cervical cancers with insulin resistance. Non-diabetic women with insulin resistance had higher risk of prevalent breast, ovarian and endomatrial cancer, which suggests special attentions to these female cancer screening and prevention.
AB - Hyperinsulinemia and insulin resistance were reported to play a crucial role in diabetes-cancer relationship. This study aimed to explore the associations between insulin resistance and several female cancers in a non-diabetic population. This cross-sectional study was conducted in 121,230 middle-aged and elderly non-diabetic women. Cancer diagnosis was self-reported and further validated by medical records. Insulin resistance was defined as homeostasis model assessment of insulin resistance (HOMA-IR) ≥ 2.50. The prevalence of both premenopausal and postmenopausal breast cancer, postmenopausal ovarian cancer and premenopausal endometrial cancer were higher in insulin-resistant participants than in insulin-sensitive participants (premenopausal breast cancer, 0.45 vs 0.28%; postmenopausal breast cancer, 0.86 vs 0.63%; postmenopausal ovarian cancer, 0.17 vs 0.09%; premenopausal endometrial cancer, 0.43 vs 0.25%, respectively, all P < 0.05). Individuals with insulin resistance had higher odds ratio (OR) of breast cancer, both premenopausal and postmenopausal (OR 1.98, 95% confidence interval (CI) 1.19-3.32; OR 1.29, 95% CI 1.01-1.63), postmenopausal ovarian cancer (OR 2.17, 95% CI 1.10-3.40) as well as total endometrial cancer (OR 1.47, 95% CI 1.02-2.12). Subgroup analysis revealed that the possitive association between insulin resistance and risk of prevalent breast cancer was observed in popualtion with younger age, overweight or obesity, higher education and impaired glucose tolerance (IGR). No relationships were observed for the risk of prevalent cervical cancers with insulin resistance. Non-diabetic women with insulin resistance had higher risk of prevalent breast, ovarian and endomatrial cancer, which suggests special attentions to these female cancer screening and prevention.
KW - Breast
KW - Endometrial and cervical cancers
KW - Insulin resistance
KW - Non-diabetic
KW - Ovarian
UR - http://www.scopus.com/inward/record.url?scp=84995571201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995571201&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84995571201
SN - 2156-6976
VL - 6
SP - 2334
EP - 2344
JO - American Journal of Cancer Research
JF - American Journal of Cancer Research
IS - 10
ER -